Body weight-based AOD-9604 dosing protocols Body composition significantly impacts peptide distribution and effectiveness
Preclinical and clinical safety data includes [5] : No evidence of mutagenic activity, chromosomal aberrations, or micronucleus formation in genotoxicity studies 6-month chronic oral administration studies in rats showed no toxicological concerns 9-month studies in cynomolgus monkeys revealed general safety Six human clinical trials spanning 0.25 mg to 30 mg doses for up to 6 months No serious adverse events or withdrawals related to AOD9604 intake No anti-AOD9604 antibodies detected, indicating low immunogenic potential No changes in vital signs, physical examinations, electrocardiograms, or safety-related laboratory parameters Research Applications A Quick Review AOD9604 is a peptide compound that has shown potential in research related to lipid metabolism, energy balance, and tissue regeneration
The Endocrine Society publishes clinical practice guidelines on obesity management that include sections on incretin-based therapies
This anti-ghrelin vaccine played an important role in maintaining energy homeostasis in a DIO murine model
The appear to be the same as what the doctor uses, but a different brand